BTK inhibitor falters in multiple sclerosis trials

Nature Reviews Neurology, Published online: 10 April 2024; doi:10.1038/s41582-024-00958-8Findings of phase III trials of the Bruton’s tyrosine kinase inhibitor evobrutinib in patients with relapsing multiple sclerosis were recently presented at the ACTRIMS Forum.

https://www.nature.com/articles/s41582-024-00958-8

Source: Nature Reviews Neurology - April 10, 2024 Category: Neurology Authors: Heather Wood Source Type: research

More News: Brain | Multiple Sclerosis | Neurology